About us

inSteps, born as a spin-off from the University of Amsterdam, is now taking its official form as inSteps B.V.. A company that employs in-silico modelling technology, aimed at propelling advancements in the treatment of severe strokes.

Our Story

After participating in the Proefdiervrij Venture Challenge in 2022 and finishing its preparatory phase with seed funding, inSteps looked ahead, harbouring objectives for its future in the world of healthcare innovation.

 

Born from the University of Amsterdam,  inSteps B.V. was founded in 2023 by Prof. Henk Marquering, Dr. Praneeta Konduri, Dr. Nerea Arrarte Terreros and Dr. Thomas Kerbusch. They hail from the Departments of Radiology & Nuclear Medicine, Biomedical Engineering & Physics at Amsterdam UMC-AMC.
 

Our Mission

 

Support device manufacturers (business-to-business services) in designing, testing, and launching new stroke treatment devices to provide acute ischemic stroke patients with better life-saving treatments.

Stroke is a major contributor to both death and disability in Europe. Thrombectomy, a crucial treatment for severe strokes caused by large vessel blockages, faces significant challenges in development and implementation. With a mere 10% success rate in introducing new stroke treatments, there’s a pressing need for faster, more efficient, and cost-effective solutions. inSteps introduces an advanced in-silico modelling platform designed for developing, testing, and evaluating endovascular devices. With this, they offer a solution to accelerate the adoption of life-saving treatments for millions of people affected by acute ischemic strokes, thereby addressing a critical healthcare need.

Our Team

Meet the dedicated team behind InSteps, a group of experts in biomedical engineering, AI, and stroke research. Our leadership combines scientific excellence with extensive experience in both academic and commercial sectors. Together, we are committed to advancing stroke treatment through innovative in-silico modeling and cutting-edge technology.

Praneeta Konduri

Chief Operating officer

Nerea Arrarte

Chief Technology officer

Prof. Henk Marquering

Chief Scientific officer

Thomas Kerbusch

Chief Executive officer

Mahsa Mojtahedi

Machine Learning Research Scientist

Thijs Kuipers

Machine Learning Research Scientist

Janneke Cruts

Biomedical Engineer

Kenia López

Computational Scientist

Future Vision

With in-silico thrombectomy already successfully commercialized and offered as a business-to-business solution, and in continued collaboration with device developers, the next frontier for the company is the patient’s bedside; making in-silico-supported personalized bedside treatment a reality. 

Request a free consultation

Contact us to learn how our platform can help optimize your medical device development and clinical trial designs.

hCaptcha